90% CI of ratio of SDs for NTI drugs [RSABE / ABEL]

posted by Satish – India, 2015-07-15 10:35 (3496 d 08:03 ago) – Posting: # 15083
Views: 4,952

Dear all,

As we know for NTI drugs guidelines Warfarin has suggested that use both (1) scaled and unscaled ABE, in addition to that (2) calculation of 90% CI of ratio of within subject standard deviation of test to reference product.

here my problem is (2). i don't know how to calculate (2). but i tried it with 'COVPRMS' of 'PROC MIXED' from normal ln transformed data (not from ilat, dlat). i calculated within subject standard deviation for test and reference using 'estimates' in 'COVPRMS'. now i just want to know am i doing it in the correct way or not?

Thanks and Regards,
Satish.

Complete thread:

UA Flag
Activity
 Admin contact
23,376 posts in 4,912 threads, 1,667 registered users;
223 visitors (0 registered, 223 guests [including 18 identified bots]).
Forum time: 17:39 CET (Europe/Vienna)

The great tragedy of Science – the slaying
of a beautiful hypothesis by an ugly fact.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5